Skip to content

Use of vijaysaradi kwath and mamajjak ghanvati in the patients of Peripheral Diabetic Neuropathy

An Exploratory Study To Evaluate The Combined Effect Of Vijaysaradi kwath And Mamajjak Ghanvati In The Management Of Madhumehjanya Updrava (Dah And Supti)Peripheral Diabetic Neuropathy - nill

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/085393
Enrollment
40
Registered
2025-04-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G328- Other specified degenerative disorders of nervous system in diseases classified elsewhere

Interventions

None listed

Sponsors

Post Graduate Institute Of Ayurved Jodhpur,Rajastan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients having cardinal symptoms of Madhumeha Upadrava like Daha Harsha Suptata will be selected 2 Diagnosed cases of Diabetic Neuropathy will be included 3 Mild to moderate Neuropathy patients having Toronto score between 6 to 11 will be included 4 Both fresh and treated cases will be included in the study 5 On-going oral hypoglycaemic agents will be continued during the study 6 No other neuropathy-managing drugs are allowed during the study period 7 Patients aged between 40 to 70 years will be included of both sexes 8 Patients who are willing to sign written consent will be included 9 Patient should be capable of obeying Pathya apathya

Exclusion criteria

Exclusion criteria: 1 IDDM (Type 1 DM) will be excluded from study 2 Patient with any other serious condition or disease which impact nerves except Diabetic Peripheral Neuropathy will be excluded 3 Pregnant and lactating women will be excluded 4 Patients having any other associated clinical condition like Dementia, Parkinson, or Stroke which influence peripheral nerve function will be excluded 5 Patient having ulceration/infection of feet 6 Medical/Surgical condition limiting functional mobility 7 Non-ambulatory patients 8 who are not willing to participate / consent

Design outcomes

Primary

MeasureTime frame
To Assessment Of Subjective And objective Parameters Before And After TreatmentTimepoint: 90 days

Secondary

MeasureTime frame
To Observe Any Side Effects IF Occur During Clinical TrialTimepoint: 90 days

Countries

India

Contacts

Public ContactDr Brahmanand Sharma

Post Graduate Institute Of Ayurved Jodhpur,Rajastan

poonampaliwal071@gmail.com7597273833

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026